Domain | Description |
---|---|
Population | • Patients with surgically resectable (cT1–3, N0–1, M0) squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic oesophagus or Siewert type 1 oesophago-gastric junction tumours • Underwent neoadjuvant therapy • Age ≥ 18 years and ≤ 75 years • European Clinical Oncology Group performance status 0–2 |
Intervention | • Minimally Invasive Oesophagectomy (MIO): supine laparoscopic gastric mobilisation and prone thoracoscopic procedure with either cervical or intra-thoracic anastomosis |
Comparator | • Open two- or three-phase oesophagectomy with cervical or intra-thoracic anastomosis |
Outcome | • 2-week and in-hospital pulmonary infection rates |
Results | • 59 patients had MIO and 56 patients underwent open surgery • 9% vs 34% pulmonary infection rate (relative risk 0.30, 95% confidence interval 0.12–0.76, p = 0.005) |
Conclusion | • This ‘first randomised trial’ comparing MIO and open approach provided ‘evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer’. |